Arrhythmogenic left ventricular cardiomyopathy as a distinct phenotype
Arrhythmogenic left ventricular cardiomyopathy (ALVC) is an inherited myocardial disease characterized by progressive fibrosis, ventricular arrhythmias, and a predominantly left-sided pattern of structural involvement. It belongs within the broader spectrum of arrhythmogenic cardiomyopathies, yet its clinical expression can differ substantially from classic arrhythmogenic right ventricular cardiomyopathy.
The phenotype is important because ventricular tachycardia or sudden cardiac arrest may precede clear left ventricular systolic dysfunction. A patient can therefore appear to have an “electrical” disorder for years before cardiac magnetic resonance imaging, family evaluation, or genetic testing reveals a broader myocardial substrate.
Recognition requires integration of electrocardiography, imaging, rhythm history, family history, and molecular data. No single finding establishes the diagnosis in every patient. Instead, clinicians must identify patterns that distinguish ALVC from myocarditis, ischemic scar, dilated cardiomyopathy, sarcoidosis, and other causes of ventricular arrhythmia.
Defining the left-dominant phenotype
ALVC generally presents with subepicardial or mid-myocardial fibrosis, often involving the inferolateral or posterolateral left ventricular wall. This distribution differs from the subendocardial or transmural scar expected after coronary artery disease. Late gadolinium enhancement on cardiac magnetic resonance imaging may be present even when ejection fraction is preserved.
Electrical manifestations can be an early clue. Patients may develop frequent premature ventricular contractions, nonsustained ventricular tachycardia, sustained monomorphic or polymorphic ventricular tachycardia, or ventricular fibrillation. Inferior and lateral T-wave inversion, low limb-lead voltages, and prolonged terminal activation may support suspicion, although these findings are neither universal nor specific.
The disease spectrum is broad. Some individuals remain stable with limited scar, while others experience recurrent ventricular arrhythmia, progressive left ventricular dysfunction, or biventricular involvement. Penetrance may be incomplete, and age-related expression means that a normal evaluation in an asymptomatic relative does not always eliminate future risk.
Genetics and myocardial injury
Pathogenic variants in desmosomal genes, including DSP, may produce a left-dominant arrhythmogenic phenotype. Other genes associated with cardiomyopathy, such as FLNC, PLN, DES, and selected non-desmosomal genes, can also be relevant depending on the clinical context and testing panel. Genetic findings must be interpreted alongside phenotype, segregation, and current variant-classification standards.
DSP-related disease deserves particular attention because patients may show episodes of myocardial injury resembling acute myocarditis. Chest pain, troponin elevation, and transient ventricular dysfunction can occur before a persistent scar pattern becomes evident. Recurrent inflammatory episodes may be associated with later ventricular arrhythmias and declining contractile function.
The proposed mechanisms include defective cell adhesion, mechanical stress, cell death, and replacement fibrosis. Exercise and other hemodynamic stresses may accelerate disease expression in susceptible individuals, although the magnitude of this effect varies by genotype and phenotype. A careful pedigree can reveal sudden death, unexplained heart failure, ventricular arrhythmia, or “myocarditis” among relatives.
Imaging and electrical evaluation
A complete assessment should combine 12-lead ECG, ambulatory monitoring, echocardiography, and cardiac magnetic resonance. Echocardiography evaluates chamber size, regional wall motion, global systolic function, and possible right ventricular involvement. Cardiac magnetic resonance is particularly valuable for mapping nonischemic fibrosis and detecting subtle regional abnormalities.
Ambulatory monitoring helps quantify premature ventricular contraction burden and identify nonsustained ventricular tachycardia. Exercise testing may expose exertional ventricular ectopy, though it should be selected carefully in patients with significant arrhythmic risk. Electrophysiologic study is not a substitute for myocardial characterization, but it can support risk assessment and guide ablation when sustained ventricular tachycardia is present.
The following findings illustrate how common diagnostic tools contribute to phenotype recognition:
| Assessment | Findings that may support ALVC | Important limitation |
|---|---|---|
| ECG | Inferolateral T-wave inversion, low voltages, conduction delay | Findings may be absent or nonspecific |
| Holter monitoring | Frequent ventricular ectopy, nonsustained ventricular tachycardia | Burden varies over time |
| Echocardiography | Regional hypokinesia or evolving LV dysfunction | Early fibrosis may be missed |
| Cardiac MRI | Subepicardial or mid-wall late gadolinium enhancement | Scar pattern requires clinical interpretation |
| Genetic testing | Pathogenic or likely pathogenic cardiomyopathy variant | A negative result does not exclude disease |
Serial imaging is often more informative than a single examination. Increasing scar burden, new regional dysfunction, or progressive ventricular ectopy can signal disease evolution. In patients with unexplained syncope, prolonged rhythm surveillance may be needed; implantable monitor guidance provides a clinically relevant framework for selecting monitoring strategies when an initial evaluation is unrevealing.
Distinguishing ALVC from similar disorders
The differential diagnosis is central because treatment and family counseling depend on the underlying substrate. Ischemic cardiomyopathy usually follows a coronary distribution, whereas ALVC more often produces subepicardial or mid-wall scar. However, an older patient may have both coronary disease and an inherited cardiomyopathy, making pattern recognition more complex.
Acute or recurrent myocarditis can resemble ALVC, particularly when troponin elevation and inflammatory symptoms dominate the presentation. Persistent or extensive inferolateral scar, recurrent episodes, ventricular arrhythmia, and a relevant family history should prompt consideration of an inherited disorder. Cardiac sarcoidosis may also produce patchy scar and conduction disease, requiring clinical, imaging, and sometimes extracardiac evaluation.
Dilated cardiomyopathy with ventricular arrhythmia is another important comparator. In ALVC, fibrosis and arrhythmia may be disproportionate to the degree of systolic impairment. This mismatch is clinically meaningful because relying solely on ejection fraction can underestimate sudden death risk.
The differential can also involve complex congenital or postoperative substrates. For patients with prior surgery and scar-related atrial tachycardia, electroanatomic mapping of scar-related atrial tachycardia demonstrates how three-dimensional substrate definition can clarify a mechanism, although atrial scar mapping should not be conflated with the ventricular fibrosis characteristic of ALVC.
Arrhythmic risk and clinical management
Risk assessment should consider sustained ventricular arrhythmia, resuscitated cardiac arrest, unexplained syncope, scar burden, ventricular dysfunction, nonsustained ventricular tachycardia, premature ventricular contraction burden, genotype, and family history. The relative importance of each factor varies across cohorts, and decisions should be individualized rather than based on a single threshold.
An implantable cardioverter-defibrillator is appropriate for survivors of cardiac arrest and many patients with documented sustained ventricular tachycardia. Primary prevention decisions are more nuanced when ejection fraction is preserved or mildly reduced. Extensive late gadolinium enhancement and a high-risk genetic or clinical profile may support device consideration even before severe systolic dysfunction develops.
Catheter ablation can reduce ventricular tachycardia episodes and device therapies, particularly when a stable scar-related circuit is present. The substrate may be predominantly epicardial or intramural, which can make endocardial ablation alone incomplete. Antiarrhythmic drugs, heart failure therapy, and management of contributing factors remain important parts of care.
Treatment planning should also account for potentially reversible contributors and device-related changes. Ventricular dysfunction caused by chronic right ventricular pacing has a different mechanism and trajectory; an overview of pacing-induced cardiomyopathy helps distinguish iatrogenic remodeling from a primary inherited arrhythmogenic cardiomyopathy.
Family screening and longitudinal care
First-degree relatives of a patient with a pathogenic variant or convincing ALVC phenotype commonly require structured evaluation. Screening may include ECG, echocardiography, ambulatory monitoring, cardiac magnetic resonance, and genetic testing when a familial variant is known. The schedule should reflect age, symptoms, genotype, and the degree of suspicion.
Genetic counseling is essential before and after testing. A pathogenic result can clarify surveillance for relatives, but a variant of uncertain significance should not be used as the sole basis for diagnosis or preventive treatment. Phenotype-based follow-up remains necessary when genetic testing is negative or inconclusive.
Lifestyle counseling should be individualized. Competitive endurance exercise and high-intensity training may increase mechanical stress and arrhythmic burden in some inherited cardiomyopathies. Advice should consider genotype, scar extent, ventricular function, symptoms, occupational demands, and the patient’s psychosocial needs rather than applying a uniform prohibition.
Longitudinal care is best delivered through a multidisciplinary team that may include electrophysiologists, heart failure specialists, imaging experts, genetic counselors, and inherited cardiomyopathy services. Reassessment is warranted after syncope, sustained palpitations, a troponin-positive episode, new ECG changes, or a decline in ventricular function.
Practical priorities for clinicians
The following principles can help translate the phenotype into daily practice:
- Suspect ALVC when ventricular arrhythmia or sudden cardiac arrest is disproportionate to left ventricular dysfunction.
- Use cardiac magnetic resonance to define nonischemic fibrosis and repeat imaging when symptoms or electrical findings evolve.
- Obtain a detailed three-generation family history, including sudden death, myocarditis-like illness, heart failure, and unexplained seizures.
- Interpret genetic results with professional counseling and avoid treating a variant of uncertain significance as diagnostic.
- Base ICD, ablation, and exercise decisions on integrated risk assessment rather than ejection fraction alone.
The phenotype also benefits from careful documentation. Recording the location and pattern of scar, ventricular arrhythmia morphology, inflammatory episodes, family findings, and changes over time improves communication among clinicians and supports more consistent research classification.
For researchers, ALVC remains an important area for phenotype-genotype correlation, prospective risk modeling, and evaluation of imaging biomarkers. Studies that distinguish left-dominant disease from generalized dilated cardiomyopathy may improve prevention strategies and clarify when inflammation, fibrosis, or electrical instability becomes clinically decisive.
Patients with unexplained ventricular arrhythmia, recurrent myocarditis-like episodes, or a family history of sudden death should receive evaluation in a specialist rhythm or inherited cardiomyopathy service. Clinicians and investigators can deepen practice through the peer-reviewed resources of the Journal of Arrhythmia, while timely recognition and family-centered surveillance may reduce preventable arrhythmic events.